Prime Medicine, Inc.
PRME
$4.04
$0.308.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 550.76% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 550.76% | -- | -- | -- | -- |
| Cost of Revenue | 0.52% | -18.70% | -5.84% | 7.22% | 15.22% |
| Gross Profit | 2.21% | 20.72% | 6.43% | -6.73% | -14.66% |
| SG&A Expenses | 15.19% | 15.61% | 27.59% | 31.33% | 38.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.08% | 7.40% | 21.75% | 35.32% | 46.47% |
| Operating Income | -3.47% | -5.84% | -21.29% | -34.94% | -46.04% |
| Income Before Tax | 1.12% | 1.28% | -27.29% | -44.49% | -48.15% |
| Income Tax Expenses | -335.09% | 100.00% | 100.00% | 25.52% | 109.22% |
| Earnings from Continuing Operations | 1.22% | 1.14% | -27.64% | -44.56% | -48.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.22% | 1.14% | -27.64% | -44.56% | -48.86% |
| EBIT | -3.47% | -5.84% | -21.29% | -34.94% | -46.04% |
| EBITDA | -2.73% | -5.20% | -21.02% | -34.69% | -45.62% |
| EPS Basic | 25.20% | 23.44% | -2.01% | 29.38% | 50.24% |
| Normalized Basic EPS | 22.08% | 17.78% | 1.74% | 27.07% | 42.26% |
| EPS Diluted | 25.20% | 23.44% | -2.01% | 29.38% | 50.24% |
| Normalized Diluted EPS | 22.08% | 17.78% | 1.74% | 27.07% | 42.26% |
| Average Basic Shares Outstanding | 32.04% | 30.37% | 26.13% | 47.84% | 84.36% |
| Average Diluted Shares Outstanding | 32.04% | 30.37% | 26.13% | 47.84% | 84.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |